AstraZeneca reported a healthy Q2 growth, outperforming closer peers like Novartis and Roche. This healthy performance was largely driven by oncology (c.45% of group sales). Moreover, the group is a front-runner in the COVID-19 vaccine race. While there were some profitability improvements as well, there’s more ground to cover vis-à-vis both peers and the group’s own historic highs. Also, apart from oncology and New CVRM, the group lacks (growth) catalysts for other areas,
31 Jul 2020
Growth continued in Q2, profitability better but more to be achieved
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Growth continued in Q2, profitability better but more to be achieved
AstraZeneca PLC (AZN:LON) | 10,689 -6841 (-0.6%) | Mkt Cap: 165,702m
- Published:
31 Jul 2020 -
Author:
Surbhit Gupta -
Pages:
5
AstraZeneca reported a healthy Q2 growth, outperforming closer peers like Novartis and Roche. This healthy performance was largely driven by oncology (c.45% of group sales). Moreover, the group is a front-runner in the COVID-19 vaccine race. While there were some profitability improvements as well, there’s more ground to cover vis-à-vis both peers and the group’s own historic highs. Also, apart from oncology and New CVRM, the group lacks (growth) catalysts for other areas,